NOVANTA INC
No SEC Form 4 filings for $NOVT in the last 30 days.
See all $NOVT insider activity →Novanta Inc. (NOVT) reported Q2 2026 revenue of $265.8 million, up 10.3% (9.3% organic). Adjusted EPS was $0.89, up 17.1%, with adjusted EBITDA of $60.7 million. The company raised 2026 guidance for revenue ($1.13B-$1.14B) and adjusted EBITDA ($273M-$278M) after completing the Riverpoint Medical acquisition, expected to add ~$65M revenue and ~$25M adjusted EBITDA in 2H26.
Conestoga Capital Advisors’ Q2 2026 investor letter said small-cap leadership improved, citing Russell 2000 results and AI and semiconductors. The firm highlighted Novanta Inc. (NASDAQ:NOVT) as a performance contributor, noting Aug. 5 close at $153.12 and 37% YoY bookings growth. Conestoga said Novanta raised its revenue outlook due to improving demand across robotics, medical tech, semiconductors, and AI.
Novanta (NASDAQ: NOVT) reported Q2 CY2026 revenue of $265.8 million, up 10.3% year on year and 1.3% above estimates, according to the company. Non-GAAP EPS was $0.89, up from $0.76 and 7.2% above consensus. It guided next-quarter revenue to $302 million (midpoint) and expects full-year EPS to rise from $3.48 to $3.94, per sell-side forecasts.
Over the past 7 days, alphai's AI scored 1 news story mentioning NOVT (NOVANTA INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent NOVT coverage spans earnings, mergers & acquisitions and financial news.
Guidance and acquisition-driven medical consumables ramp are likely to drive near-term estimate revisions and positioning around 2026 margin trajectory.
The article frames a demand broadening story for Novanta, anchored on a 37% YoY bookings increase and an implied revenue-outlook raise.
Beat-and-raise style quarter with upside revenue guidance and EPS beat, likely supporting near-term multiple and momentum.
Guidance upside plus acquisition-driven growth and margin assumptions create a near-term repricing risk for NOVT, especially around Q3 expectations.
The 8-K discloses a fresh earnings and guidance package plus acquisition-driven outlook, which can drive near-term repricing versus prior expectations.
alphai scores every news story that mentions NOVT with an AI model for sentiment and relevance, and aggregates insider trades from NOVANTA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Novanta Inc. (NOVT) reported Q2 2026 revenue of $265.8 million, up 10.3% (9.3% organic). Adjusted EPS was $0.89, up 17.1%, with adjusted EBITDA of $60.7 million. The company raised 2026 guidance for revenue ($1.13B-$1.14B) and adjusted EBITDA ($273M-$278M) after completing the Riverpoint Medical acquisition, expected to add ~$65M revenue and ~$25M adjusted EBITDA in 2H26.
6 min readConestoga Capital Advisors’ Q2 2026 investor letter said small-cap leadership improved, citing Russell 2000 results and AI and semiconductors. The firm highlighted Novanta Inc. (NASDAQ:NOVT) as a performance contributor, noting Aug. 5 close at $153.12 and 37% YoY bookings growth. Conestoga said Novanta raised its revenue outlook due to improving demand across robotics, medical tech, semiconductors, and AI.
4 min readNovanta (NASDAQ: NOVT) reported Q2 CY2026 revenue of $265.8 million, up 10.3% year on year and 1.3% above estimates, according to the company. Non-GAAP EPS was $0.89, up from $0.76 and 7.2% above consensus. It guided next-quarter revenue to $302 million (midpoint) and expects full-year EPS to rise from $3.48 to $3.94, per sell-side forecasts.
4 min readNovanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.
6 min readNOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 novt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE August 5, 2026 Novanta Announces Financial Results for the Second Quarter 2026 • Second Quarter 2026 GAAP Revenue increased 10% to $266 million • Second Quarter 2026 GAAP Net Income was $13 million, and
6 min readNovanta Inc. (Nasdaq: NOVT) said it has completed its acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta expects the deal to double recurring medical consumables revenue to about $300 million, raise medical end-market exposure to 60%, deliver high single-digit ROIC by year three, and add $0.18 to $0.25 of adjusted EPS in 2027.
5 min readNOVANTA INC (NOVT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0001076930 0001076930 novt:SixPointFiveZeroPercentTangibleEquityUnitsMember 2026-07-22 2026-07-22 0001076930 us-gaap:CommonStockMember 2026-07-22 2026-07-22 0001076930 2026-07-22 2026-07-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
3 min readGlastra Matthijs (Chief Executive Officer) sold 6,500 shares of NOVANTA INC (NOVT) at an average of $161.13 ($160.13–$164.20, $1.05M total) across 5 trades on 2026-07-02 under a Rule 10b5-1 trading plan.
1 min readUS stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.
7 min readNOVANTA INC (NOVT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 novt-ex10_1.htm EX-10.1 EX-10.1 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of June 8, 2026, by and among Novanta Inc., a company continued and existing under the laws of the Province of New Brunswick, C
6 min read
